DongKook Pharmaceutical Co. Ltd (086450) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DongKook Pharmaceutical Co. Ltd (086450) has a cash flow conversion efficiency ratio of 0.040x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩32.26 Billion ≈ $21.86 Million USD) by net assets (₩797.63 Billion ≈ $540.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of DongKook Pharmaceutical Co. Ltd for the company's overall valuation and market capitalisation.
DongKook Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how DongKook Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DongKook Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DongKook Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Explore DongKook Pharmaceutical Co. Ltd (086450) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Creditwest Faktoring AS
IS:CRDFA
|
-0.088x |
|
NMP Acquisition Corp.
NASDAQ:NMP
|
-0.002x |
|
Triple i Logistics Public Company Limited
BK:III
|
0.022x |
|
Whanin Pharm
KO:016580
|
0.022x |
|
BARKBY GRP PLC LS 000860
F:3WY
|
N/A |
|
WTK Holdings Bhd
KLSE:4243
|
0.074x |
|
Resources Connection Inc
F:RCO
|
-0.047x |
|
Shimmick Corporation Common Stock
NASDAQ:SHIM
|
-0.011x |
Annual Cash Flow Conversion Efficiency for DongKook Pharmaceutical Co. Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of DongKook Pharmaceutical Co. Ltd from 2013 to 2025. View 086450 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩763.74 Billion ≈ $517.57 Million |
₩68.76 Billion ≈ $46.60 Million |
0.090x | -19.66% |
| 2024-12-31 | ₩678.98 Billion ≈ $460.13 Million |
₩76.09 Billion ≈ $51.57 Million |
0.112x | +54.50% |
| 2023-12-31 | ₩576.17 Billion ≈ $390.46 Million |
₩41.79 Billion ≈ $28.32 Million |
0.073x | -11.00% |
| 2022-12-31 | ₩501.94 Billion ≈ $340.16 Million |
₩40.91 Billion ≈ $27.72 Million |
0.082x | -17.03% |
| 2021-12-31 | ₩454.57 Billion ≈ $308.05 Million |
₩44.65 Billion ≈ $30.26 Million |
0.098x | -31.63% |
| 2020-12-31 | ₩411.37 Billion ≈ $278.78 Million |
₩59.11 Billion ≈ $40.06 Million |
0.144x | -24.96% |
| 2019-12-31 | ₩362.87 Billion ≈ $245.91 Million |
₩69.48 Billion ≈ $47.09 Million |
0.191x | +80.48% |
| 2018-12-31 | ₩313.02 Billion ≈ $212.13 Million |
₩33.21 Billion ≈ $22.51 Million |
0.106x | -2.29% |
| 2017-12-31 | ₩263.94 Billion ≈ $178.87 Million |
₩28.66 Billion ≈ $19.42 Million |
0.109x | -34.62% |
| 2016-12-31 | ₩237.32 Billion ≈ $160.83 Million |
₩39.41 Billion ≈ $26.71 Million |
0.166x | +22.14% |
| 2015-12-31 | ₩199.62 Billion ≈ $135.28 Million |
₩27.14 Billion ≈ $18.39 Million |
0.136x | +5.59% |
| 2014-12-31 | ₩176.57 Billion ≈ $119.66 Million |
₩22.74 Billion ≈ $15.41 Million |
0.129x | +5.20% |
| 2013-12-31 | ₩162.24 Billion ≈ $109.95 Million |
₩19.86 Billion ≈ $13.46 Million |
0.122x | -- |
About DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more